HCW Biologics Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +356.2%
EBITDA: +97.2%
EBIT: +73.1%
EPS: —
Free cash flow: +19.7%
Operating cash flow: +19.0%

Forward estimates

Revenue: -99.7%
EBITDA: +98.3%
EPS: +99.0%

Three-year CAGR

Revenue: -79.9%
EBITDA: +79.5%
EBIT: +61.8%
Net income: +73.5%
EPS: —
Free cash flow: +7.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.